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Background: Inflammatory myofibroblast tumor (IMT) is a rare tumor with obscure
etiopathogenesis in which different inflammatory cells and myofibroblastic spindle cells
are seen histologically. Although the majority of these neoplasms have a benign clinical
course, the malignant form has also been reported. The gold standard is surgical
treatment for complete removal. Our report describes a 50-year-old woman who
underwent surgery for IMT of the lung. The aim is to determine whether cancer stem
cells may be present in IMT of the lung.
Methods: In April 2018, the patient underwent surgery for tumor mass asportation
through lateral thoracotomy. The histology of the tumor was consistent with IMT of
the lung. The ALDEFLUOR assay, after tissue digestion, was used to identify and sort
human lung cancer cells expressing high and low aldehyde dehydrogenase (ALDH)
activity. SOX2, NANOG, OCT-4, and c-MYC positivity were additionally determined
by immunohistochemistry.
Results: The specimen contained 1.10% ALDHhigh cells among all viable lung
cancer cells, which indicates the population of cancer stem cells is not negligible.
Immunohistochemically assessed cell positivity for ALDH1A1, SOX2, NANOG, OCT-4,
and c-MYC, which are considered as lung cancer stem-like cells markers.
Conclusion: For the first time, we demonstrated the presence of cancer stem cells in a
case of IMT of the lung. This finding may provide a base for considering new pathological
and molecular aspects of this tumor. This perspective suggests further studies to
understand the possibility of developing recurrence depending on the presence of cancer
stem cells.
Keywords: inflammatory myofibroblastic tumor of the lung, cancer stem cells, cancer stem-like cells, mitosis,
target therapy
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INTRODUCTION
The inflammatory myofibroblastic tumor (IMT), first described
by Brunn in 1937, is an extremely rare type of inflammatory
pseudo-tumor. The prevalence is between 0.04 and 0.7%,
independent of gender and race (1–3). It is debated whether an
IMT is a benign or malignant lesion and this is often challenging
for further clinical decisions. However, the lungs are considered
the most common site for the presentation of this tumor (1).
There are cases of recurrence described in the literature, not
only in the lungs but also in other organs, however the recurrence
rate at 10 year survival is lower than 90% (4, 5). Beside this aspect,
the pathological nature of this tumor is still debated.
In 2002 the World Health Organization classified IMT as
an intermediate grade malignancy (6). One of the most recent
discoveries is related to chromosomal translocation involving
the ALK gene, which seems to be present in 50% of cases with
malignant characteristics (7). The treatment of choice for IMTs is
surgical resection in order to guarantee a favorable prognosis (4).
Our work aims to detect the presence of cancer stem-like cells
(CSCs) in a case of IMT of the lung by immunohistochemical
testing for the most common CSCs markers, with aldehyde
dehydrogenase (ALDH), as well as for the presence of pluripotent
transcription factors such as OCT4, SOX-2, NANOG, and C-
MYC, which modulate biological CSC activities (8–10). This will
provide a base for further studies with a larger cohort of patients
considering the presence of CSCs as a new pathological marker
and a possible predictive factor of aggressiveness in this type
of tumor.
METHODS
Case Presentation
In April 2018, a 47-year-old woman came to our attention for
dyspnea and tachycardia under exertion. An x-ray of the chest
showed a large mass in the left hemithorax. A CT scan with
enhancement presented a 40 × 30 cm mass involving the left
upper lobe of the lung. A CT guided biopsy gave a diagnosis
of benign lung tumor. An Emission Tomography – Computed
Tomography (PET/CT) scan showed a very mild uptake at the
level of the nodule (SUVmax= 2.3) with no other signs of uptake
in other parts of the body (Figure 1).
For the symptomatology and the dimension of the mass,
the patient underwent a left upper lobectomy through lateral
thoracotomy. The final histology showed an IMT of the lung.
The cells were positive for actin in smooth muscle, although
negative for ALK, MNF116, and estrogenic receptors, as well as
for tuberculosis.
Patient underwent a clinical check ten days after surgery by
the oncologist who suggested a period of follow up every 6
months for the first and second year from surgery, and every year
after the second year, for a total of 5 years of radiological and
clinical monitoring.
Abbreviations: ALDH, aldehyde dehydrogenase; FACS, fluorescence-activated
cell sorting; CSCs, cancer stem cells; SSC, side scatter; FSC, forward scattered; IMT,
inflammatory myofibroblastic tumor.
Cells Extraction and FACS Analysis
Sterile Dulbecco’s PBS (L1825-BC—Merck Millipore) was used
to wash the IMT tissue, then minced mechanically into
millimetric pieces, and further digested using MACSTM C-
Tube (Miltenyi) tumor dissociation kit, according to the
manufacturer’s instructions. The tissue was digested for 60min
at 37◦C, filtered through a sterile cell strainer and centrifuged at
300× g for 5min, then resuspended in a DMEM andHAM’S F12
media mixture (2:1) (Gibco) containing penicillin-streptomycin
and glutamine. The primary single-cell suspension was diluted in
an ALDEFLUOR buffer containing BODIPY-aminoacetaldehyde
(STEMCELL Technologies, Vancouver, BC). The morphology
of the cell population was studied using side scatter (SSC) and
forward scatter (FSC). Dead cells were identified and eliminated
using 7-AAD (7-amino-actinomycin D) staining. Cell sorting
and ALDH analysis were performed using a FACS-ARIA III
(Becton Dickinson, Franklin Lakes, NJ). Results were analyzed by
fluorescence-activated cell sorting (FACS) Diva software (Becton
Dickinson). ALDHhigh gate was included as gating strategy
(11–13).
Immunohistochemistry
The patient’s slides were deparaffinized, rehydrated and then
washed in PBS. Sodium citrate buffer was used for antigen
retrieval. Samples were incubated with anti- ALDH1A1 (1:100)
(Abcam, Cambridge, UK), anti-SOX2 (1:200) (MA1-014
Thermo Fisher Scientific, Meridian Road Rockford, IL, USA),
anti-NANOG (1:200) (Thermo Fisher Scientific, Meridian
Road Rockford, IL, USA), anti-OCT-4 (Cell Marque, Sierra
College Blvd. Rocklin, California United States and anti-c-
MYC (Ventana Medical Systems, Tucson, Arizona, USA)
overnight at 4◦C. Images were collected and the positivity
was evaluated with Zeiss AxioCam ICc 3 High-Resolution
through an Axioskop microscope camera. Section samples
were investigated to evaluate the immunoreactivity to the
markers used. A semi-quantitative method based on the
evaluation of the positivity of the tumor cells was used. Here
are shown the score classes: 0 (<5% positive), 1 (5 to 25%
positive), 2 (>25 to 50% positive), 3 (>50 to 75% positive),
and 4 (>75% positive) (14). Sections were scored by two
trained investigators, blinded to patient’s outcome and other
clinical findings.
RESULTS
Clinical Setting
The patient was discharged after six days from surgery with
no complications. A chest x-ray after one week was normal
following the operation. The patient underwent follow up and no
recurrence was observed within a year after surgery.
ALDHhigh Stem Cells Were Identified in
Primary Cells of an IMT of the Lung
Tumor tissue dissociation efficiently released cancer cells
characterized by a heterogeneous morphology, as illustrated
in the widespread FSC and SSC values (Figure 2) (11–
13). The mean viability of the samples was 99.7% based
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FIGURE 1 | Total body PET/CT scan. Lung nodule at the upper left lobe showed a very low uptake of the lesion.
on 7-AAD staining. These data further confirmed that
the developed dissociation procedure was a non-toxic
approach to isolating cells from tumor tissues. The CSCs
were physically separated from the bulk parental tumor cells
and recovered by FACS according to the following gating
strategy. Tumor cells were first identified based on their
morphological parameters (FSC/SSC), and the ALDH activity
was measured in the 7-AAD negative cell population only
(Figure 2). ALDHlow and ALDHhigh cells were both selected
and sorted (Figure 2). An ALDHhigh subpopulation accounted
for 1.10% of all viable lung cancer cells, which indicates that
a non-negligible population of tumor cells had characteristics
of CSCs.
Immunohistochemical Evaluation of the
ALDH1A1, SOX2, NANOG, OCT-4, and
c-MYC Stem Cell Markers in an IMT of the
Lung
To further evaluate the stemness of the cells extracted from
the tumor biopsy, SOX2 immunohistochemistry was performed.
Positive cells from tissue slides, represented by brown nuclei,
were analyzed at 10x and 20x magnification. As expected from
the FACS analysis, a non-negligible percentage of the cells were
positive for ALDH1A1, SOX2, NANOG, OCT-4, and c-MYC
(Figure 3).
DISCUSSION
In our report we first described the presence of cancer stem-
like cells in a case of IMT of the lung. The connection
between benign and malignant lesions has been investigated for
a long time (15–17). Besides the different causes of malignancy,
infectious disease may be one of the main causes of induced
tumorigenesis (18). In fact the inflammatory microenvironment
seems to be the key for the development and maintenance
of the CSCs’ niche (19). These mechanisms can be justified
through the enhancement of proliferation, induction and
metastatic signaling (15). In this report, our aim is to highlight
the presence of cancer stem-like cells in combination with
IMT inflammatory components. In particular, the possibility
of emerging inflammatory mechanisms inducing stemness of
CSCs has been previously described (19). In breast cancer,
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FIGURE 2 | FACS analysis. Cytofluorimetric analysis of ALDHhigh cells in a case of lung myofibroblastic tumor.
for example, the inflammatory factors are considered as one
of the main causes of tumorigenesis (20, 21). However, the
histogenesis of IMTs is unclear at the moment; some researchers
suggest that IMTs are benign lesions with impacts for surgery,
trauma, radiotherapy, steroids, and infectious agents, without
convincing explanations for the entire scientific community
(22–24). There are other hypothesis suggesting that IMTs are
tumors related to genetic modifications, such as the recurrent
involvement of chromosomal region 2p23, which seems to
induce the aggressive local behavior and metastasis of this
tumor (25). In particular, Coffin et al. demonstrated that
some IMTs are neoplastic lesions with clonal aberrations
(25). Additionally, it is very difficult to define histologically
specific characteristics for this disease which can be used
to define possible markers, and this is probably due to
the impossibility of distinguishing heterogeneity in clinical
aspects (26).
As a result, several teams tried to define lesions as falling under
the category of IMT.
The World Health Organization has classified IMTs as a
distinct entity, being tumors of intermediate biological potential
for their capacity to generate local recurrence and, in some cases,
distant metastasis (27).
Histologically IMTs are described as cellular or fascicular
fibroblastic proliferations associated with chronic inflammatory
infiltrate (27). It has been suggested that there are histologic
criteria to define the malignant transformation as, for example,
round cells associated with necrosis, large nucleoli, several
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FIGURE 3 | Immunohistochemistry of lung myofibroblastic tumor. Representative immunohistochemical staining of ALDH1A1, SOX2, NANOG, OCT-4, and c-MYC
stem cell markers on a myofibroblastic tumor. Images were shown at 10x and 20x magnification.
mitoses, etc. (27). However, the main characteristic of these
tumors is the myofibroblast, which justified the term of
“inflammatory myofibroblastic tumors” (26). However, no
attention until now has been given to the possible presence of
cancer stem-cells in this tumor (27–30). Our study represents the
first attempt at highlighting new cell populations that may be the
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key to better characterizing this type of tumor. In conclusion, we
aim to determine new pathological markers as well as to aid the
development of targeted therapies.
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